恩维-抗体共同进化确定B细胞培养为HIV-1 V2顶峰的主要瓶,广泛中和抗体发育
bioRxiv : the preprint server for biology
|June 12, 2025
概括
广泛中和抗体 (bNAbs) 很少在HIV-1感染期间产生. 这项研究表明,B细胞原始化的低效率,而不是抗体成熟,是中V2顶峰bNAbs发展的主要障碍.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 艾滋病毒-1研究研究
背景情况:
- 广泛中和抗体 (bNAbs) 对于控制HIV-1至关重要,但在自然感染期间很少产生.
- 了解bNAb开发的障碍对于设计有效的HIV-1疫苗至关重要.
研究的目的:
- 识别阻碍广泛中和抗体 (bNAbs) 在猿人免疫缺陷病毒 (SHIV) 感染期间准V2顶部的发展的障碍.
- 确定病毒包膜 (Env) 蛋白与抗体反应之间的共同进化途径.
主要方法:
- 对122只感染各种SHIV的 rhesus进行了纵向研究.
- 在10只中分析了从B细胞原始化到bNAb发育的Env抗体共同进化.
- 对抗体发育的遗传学分析和特定Env突变的鉴定.
主要成果:
- V2顶部被确定为bNAbs.的最常见目标.
- 发现特定的Env子集优先引起V2顶点向的bNAbs.
- 允许的Env进化与V2顶峰C链附近的最小突变促进了bNAb的发展,而缺席表明了初始化失败.
结论:
- 在B细胞原始化的低效率,而不是复杂的亲和力成熟,是引起SHIV感染的V2顶峰bNAbs的主要障碍.
- 特定的HIV-1 Env序列可以被确定并作为潜在的疫苗平台推广,以促进bNAb的开发.
更多相关视频
07:10Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
Published on: September 14, 2014
14.3K
00:09Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations
Published on: August 22, 2019
10.6K
相关概念视频
B Cell Activation and Differentiation
1.6K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.6K
Antigens Involved in Adaptive Immunity
470
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
470
Diversity of Antigen Receptors
536
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
536
Immune Response Against Viral Pathogens
764
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
764
Cross-reactivity
31.0K
Overview
31.0K
Humoral Immune Responses
72.2K
Overview
72.2K
